Form 4: Lilly Endowment Sells $17.3M Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 15,632 common shares for approximately $17.3 million under a pre-arranged trading plan.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 15,632 shares of common stock on November 25, 2025.
• The sales were executed in three separate transactions under a Rule 10b5-1 pre-arranged trading plan.
• The first transaction involved 5,043 shares sold at a weighted average price of $1,108.71, totaling approximately $5.59 million.
• The second transaction involved 9,249 shares sold at a weighted average price of $1,109.449, totaling approximately $10.26 million.
• The third transaction involved 1,340 shares sold at a weighted average price of $1,110.527, totaling approximately $1.49 million.
• Following these transactions, Lilly Endowment Inc. directly owns 92,196,978 shares of Eli Lilly & Co. common stock.
• This filing represents transactions #31 through #33 of 33 total transactions, as part of the second of two Forms 4 filed on November 26, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the transaction was executed under a pre-arranged 10b5-1 plan, which mitigates concerns about immediate negative sentiment or new adverse information. It's a routine disclosure of a planned divestment by a significant shareholder.

Positives

• The sales were conducted under a Rule 10b5-1 pre-arranged trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• A significant insider, a 10% owner, sold a substantial number of shares, which could be interpreted as a reduction in their proportional stake.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Management Comments

• This is the second of two Forms 4 filed by the Reporting Person on same date, November 26, 2025, representing transactions #31 through #33 of 33 total transactions.

Industry Context

This Form 4 filing reports an insider transaction and does not provide broader industry context. Eli Lilly & Co. operates in the pharmaceutical industry, which is characterized by significant R&D investment, patent protection, regulatory approvals, and global market competition. Insider sales, even under 10b5-1 plans, are routinely monitored by investors for potential signals regarding management's or significant shareholders' confidence in the company's future prospects.

Comparison to Industry Standards

• This filing details an insider stock sale, which is a standard disclosure requirement for 10% owners. There are no specific company or project results to compare to industry benchmarks. The transaction itself is a routine disclosure of a large shareholder's activity.

Related Party Transactions

• The reported transactions are sales of common stock by Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., making them related party transactions by definition. No other related party dealings are disclosed.

Stakeholder Impact

• Shareholders: The sale by a significant 10% owner could be perceived by other shareholders as a slight reduction in insider confidence, although the 10b5-1 plan mitigates this. The total shares outstanding remain unchanged.
• Company: No direct operational impact on Eli Lilly & Co. is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale by a 10% owner under a pre-arranged 10b5-1 trading plan. Such planned sales typically do not reflect new material information about the company's performance or outlook. While a large sale by a significant shareholder might warrant attention, the context of a 10b5-1 plan suggests a pre-determined financial strategy by the endowment rather than a reaction to adverse company-specific news. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation based solely on this filing. Investors should continue to hold and monitor broader company fundamentals and market conditions.

Keywords

Eli Lilly, LLY, Lilly Endowment, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, pharmaceutical, healthcare